The two major components that need to be available for the successful implementation of PDT in LMICs are affordable photosensitizers and light sources. The prodrug -aminolevulinic acid (ALA), which preferentially converts to the photosensitizer protoporphyrin IX (PpIX) in tumors, can be stored at room temperature without specialty storage equipment. ALA can be easily administered to patients topically, as a cream, or orally, through ingestion in beverages, without sophisticated medical setups or highly trained healthcare professionals. Moreover, ALA is readily available in LMICs such as India (DUSA Pharmaceuticals, Inc., a subsidiary of Sun Pharmaceutical Industries Ltd., an India-based conglomerate). The second major component of PDT is the light source required to initiate photodynamic action.10 Often, light sources are expensive, bulky, and immobile. Moreover, current PDT light sources (e.g., lasers) typically require electricity for continuous operation, a feature not available in developing countries due to frequent electrical power failure. In recent years, there have been several attempts to replace lasers with light-emitting diode (LED)-based light sources to reduce cost and increase flexibility of use in sites outside major hospitals.11 In an effort to make PDT a viable treatment in LMICs and LMIC-like settings, here we evaluate a battery-powered LED light source which, in addition to providing reduced costs, could also be independent of plug-in electricity during treatment and be powered using precharged batteries.